ASP Isotopes Inc. 10-Q Summary: Q3 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. ASP Isotopes Inc. is a development-stage advanced materials company focused on isotope enrichment technologies (ASP and Quantum Enrichment) for medical, semiconductor, and nuclear fuel applications. The company operates through three segments: Specialist Isotopes and Related Services, Nuclear Fuels (via subsidiary Quantum Leap Energy or QLE), and Construction Services (via the August 2025 acquisition of Skyline Builders Group Holding Limited).
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $4.89 million | $1.09 million | $7.19 million | $2.95 million |
| Gross Profit | $0.42 million | $0.29 million | $1.32 million | $0.99 million |
| Net Loss (Attributable to Shareholders) | $(12.87) million | $(7.27) million | $(96.38) million | $(25.93) million |
| Cash and Cash Equivalents | $113.94 million (as of Sept 30, 2025) | |||
| Total Debt (Current + Noncurrent) | $13.94 million (excluding convertible notes) | |||
| Convertible Notes Payable (Fair Value) | $97.98 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 349% year-over-year for the nine months ended September 30, 2025, driven primarily by the acquisition of Skyline (Construction Services) which contributed $3.62 million in revenue, and growth in the Specialist Isotopes segment (PET Labs).
- Net Loss Expansion: The net loss widened significantly to $96.38 million for the nine months ended September 30, 2025, compared to $25.93 million in the prior year. This was largely due to a $64.54 million non-cash expense related to the change in fair value of convertible notes payable.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by $12.72 million year-over-year (YTD), attributed to increased headcount, professional fees for corporate development, and facility costs. R&D expenses increased by $3.79 million YTD due to manufacturing engineering testing and personnel costs.
- Balance Sheet: Total assets grew from $94.35 million to $225.89 million, reflecting cash raised from equity offerings and the assets acquired from Skyline.
Guidance, Outlook, and Risks
- Commercialization Timeline: The company anticipates shipping the first commercial batch of enriched C-12 in Q4 2025, Si-28 in Q1 2026, and C-14 in H1 2026. Commercial quantities of Yb-176 are expected in H1 2026.
- Strategic Separation: ASP Isotopes plans to separate its Nuclear Fuels business (QLE) into a standalone public company, aiming to initiate the listing process in Q4 2025. A draft S-1 was confidentially submitted in November 2025.
- Renergen Acquisition: The company is pursuing the acquisition of Renergen Limited. A $30 million bridge loan was extended to Renergen, with repayment due November 28, 2025. The transaction is subject to regulatory and lender approvals.
- Liquidity: Management expects cash on hand ($113.9 million) plus proceeds from a $199.7 million October 2025 offering and $72.2 million in QLE convertible notes (November 2025) to fund operations for more than 12 months.
- Risks: Key risks include the ability to achieve profitability, regulatory approvals for uranium enrichment, the success of the Renergen acquisition, and the potential inability to raise additional capital. A securities class action lawsuit is pending regarding alleged misleading statements.
Investor Verification Checklist
- Convertible Note Valuation: Verify the assumptions used to calculate the $64.5 million fair value adjustment on convertible notes, as this significantly impacts reported net loss.
- Renergen Loan Repayment: Monitor the status of the $30 million loan to Renergen due November 28, 2025, and the progress of regulatory approvals for the acquisition.
- QLE IPO Progress: Track the status of the QLE separation and IPO filing, as this is a key strategic milestone.
- Isotope Shipping Dates: Confirm the actual shipment dates for C-12, Si-28, and C-14 against the stated Q4 2025 and 2026 targets.
- Legal Proceedings: Review updates on the pending securities class action lawsuit filed in December 2024.